The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Otsuka and H. Lundbeck’s drug REXULTI for the treatment of schizophrenia in pediatric patients aged 13 to 17. Schizophrenia is a life-long serious disease that is often characterized by hallucinations, disorganized behavior, speech, and thought. REXULTI (brexpiprazole) is an orally taken atypical antipsychotic drug that works as a partial agonist for the 5-HT1A and D2 receptors and is an antagonist for the 5HT2A receptors. Due to the complexity of schizophrenia, options for treatment are typically a combination of therapy options and medicines to manage the symptoms. FDA sNDA’s are approved to allow for companies to make changes to a drug that has already received a new drug application (NDA). Otsuka and H. Lundbeck are pharmaceutical companies that develop treatment options to address unmet medical needs for general health concerns and brain diseases.
Read more here.
